Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, TX, United States of America.
Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United States of America.
PLoS One. 2023 Feb 28;18(2):e0282309. doi: 10.1371/journal.pone.0282309. eCollection 2023.
Polygenic risk scores (PRS) hold the promise to refine prognostication in hepatocellular cancer (HCC). The few available HCC PRS include germline risk variants identified among individuals of mostly European ancestry, but data are lacking on the transportability of these PRS in multiethnic U.S patients with cirrhosis from multiple etiologies.
We used data from 1644 patients with cirrhosis enrolled in two prospective cohort studies in the U.S. Patients were followed until HCC diagnosis, death, liver transplantation, or last study visit through June 30, 2021. The high-risk variants in PNPLA3-MBOAT7-TM6SF2-GCKR were combined in a PRS and we evaluated its association with HCC. Discriminatory accuracy was assessed using the C-statistic.
During 4,759 person-years of follow-up, 93 patients developed HCC. Mean age was 59.8 years, 68.6% were male, 27.2% Hispanic, 25.1% non-Hispanic Black, 25.7% had NAFLD, 42.1% had heavy alcohol use, and 19.5% had active HCV. HCC risk increased by 134% per unit increase in PRS (HR = 2.30; 95% CI, 1.35-3.92). Compared to cirrhosis patients in the lowest tertile of the PRS, those in the highest tertile had 2-fold higher risk of HCC (HR = 2.05; 95% CI, 1.22-3.44). The PRS alone had modest discriminatory ability (C-statistic = 0.58; 95% CI, 0.52-0.63); however, adding PRS to a predictive model with traditional HCC risk factors had a C-statistic of 0.70 (95% CI, 0.64-0.76), increasing from 0.68 without the PRS (p = 0.0012).
Our findings suggest that PRS may enhance risk prediction for HCC in contemporary U.S. cirrhosis patients.
多基因风险评分(PRS)有望改善肝细胞癌(HCC)的预后。少数可用的 HCC PRS 包括在主要来自欧洲血统的个体中发现的种系风险变异,但缺乏关于这些 PRS 在具有多种病因的美国多民族肝硬化患者中的可转移性的数据。
我们使用了来自美国两项前瞻性队列研究的 1644 名肝硬化患者的数据。患者在 HCC 诊断、死亡、肝移植或 2021 年 6 月 30 日前最后一次研究随访前,接受随访。将 PNPLA3-MBOAT7-TM6SF2-GCKR 中的高危变异组合成 PRS,并评估其与 HCC 的相关性。使用 C 统计量评估判别准确性。
在 4759 人年的随访期间,93 名患者发生 HCC。平均年龄为 59.8 岁,68.6%为男性,27.2%为西班牙裔,25.1%为非西班牙裔黑人,25.7%患有非酒精性脂肪性肝病,42.1%有大量饮酒史,19.5%患有慢性丙型肝炎。PRS 每增加一个单位, HCC 风险增加 134%(HR=2.30;95%CI,1.35-3.92)。与 PRS 最低三分位的肝硬化患者相比,PRS 最高三分位的患者 HCC 风险增加 2 倍(HR=2.05;95%CI,1.22-3.44)。PRS 本身具有适度的判别能力(C 统计量=0.58;95%CI,0.52-0.63);然而,将 PRS 添加到具有传统 HCC 风险因素的预测模型中,C 统计量为 0.70(95%CI,0.64-0.76),与不使用 PRS 时的 0.68 相比有所增加(p=0.0012)。
我们的发现表明,PRS 可能增强对当代美国肝硬化患者 HCC 的风险预测。